Shenzhen Zhongjia Biomedical Technology Co., Ltd. Shenzhen Zhongjia Biomedical Technology Co., Ltd.

Industry News

Industry News

Focus on MLD: Why Should This Rare Leukodystrophy Be Seen Earlier?

2026-10-23

Metachromatic leukodystrophy (MLD) is a rare inherited neurometabolic disease belonging to the lysosomal storage disorders. Due to insufficient ARSA enzyme activity, substances such as sulfatides gradually accumulate in nervous tissue, damaging the myelin sheath of the central and peripheral nervous systems and leading to progressive decline in motor, cognitive and language functions.

MLD is usually inherited in an autosomal recessive manner. This means both parents may carry the pathogenic gene without obvious symptoms, so a family history is not always evident. The disease can onset in late infancy, adolescence or even adulthood, and the rate of progression and clinical manifestations vary among types.

Common manifestations include motor developmental regression, abnormal muscle tone, difficulty walking, peripheral neuropathy, impaired language expression and delayed cognitive development. Because early symptoms may resemble other developmental problems, MLD sometimes faces diagnostic delay. For children and adolescents with unexplained motor regression or abnormal nerve conduction, clinicians can use ARSA enzyme activity testing, genetic testing and neuroimaging for differential diagnosis.

Currently, MLD management emphasizes multidisciplinary collaboration, including neurology, rehabilitation, genetic counseling, nutrition and supportive care. Research directions such as enzyme replacement therapy, hematopoietic stem cell transplantation and gene therapy are bringing new treatment possibilities to some patients with MLD. However, experts note that the treatment window, eligible age and disease stage must be comprehensively assessed by a professional team.

For families, genetic counseling after diagnosis is equally important. By identifying the pathogenic gene, family members can understand recurrence risks and, when necessary, discuss reproductive choices and prenatal diagnosis.

MLD is rare, but early recognition, accurate diagnosis and timely intervention can help patients receive more appropriate support. Raising public and primary-care physicians' awareness of MLD is an important step toward shortening the diagnostic journey and helping more families avoid detours.

Related News

  • Focus on MLD: Why Should This Rare Leukodystrophy Be Seen Earlier?

    2026-10-23

  • Can Alzheimer’s Risk Be Reduced? WHO Guidance Highlights Modifiable Dementia Risk Factors

    2026-9-28

  • Alzheimer's Treatment Advances: From Amyloid to Tau Multi-Target Research

    2026-9-28

  • New Progress in Early Alzheimer's Screening: Blood Tests Become an Important Research Direction

    2026-9-28

  • Great News! Another Zhongjia Medium Gets FDA DMF Filing

    2026-7-23